Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease

Marketwired February 26, 2015

Revive Therapeutics Announces Results for the Three and Six Months Ended December 31, 2014

Marketwired February 11, 2015

Revive Therapeutics Announces Initiation of a Phase 2A Study of REV-002 (Bucillamine) in Patients With Gout

Marketwired January 29, 2015

Revive Therapeutics Enters Into Research Collaboration With Rettsyndrome.org

Marketwired January 15, 2015

Revive Therapeutics Completes Prospectus Offering of Approximately $3,000,000

Marketwired December 18, 2014

Revive Therapeutics Prices and Files Final Prospectus for Equity Financing

Canada NewsWire December 5, 2014

Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2014

Marketwired November 26, 2014

Revive Therapeutics Ltd. Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout

Marketwired November 26, 2014

Revive Therapeutics Ltd. Announces Receipt of Prospectus for Public Offering of Common Shares

Marketwired November 4, 2014

CORRECTION FROM SOURCE: Revive Therapeutics Ltd. Announcing Receipt for Preliminary Prospectus Is Pending

Marketwired November 4, 2014

Revive Therapeutics Ltd. Announces Public Offering of Common Shares

Marketwired November 3, 2014

Revive Therapeutics Ltd. Submits IND Application to the US FDA for the Clinical Development of Bucillamine for the Treatment of Gout

Marketwired October 30, 2014

Revive Therapeutics Ltd. Applies for Orphan Drug Designation to FDA for Treatment of Rett Syndrome

Marketwired October 28, 2014

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2014

Marketwired September 16, 2014

Revive Therapeutics Ltd. Names Dr. Robert A. Terkeltaub, MD, as Principal Investigator for Upcoming Gout Study

Marketwired September 11, 2014

Revive Therapeutics Ltd. Announces Positive Results of REV-001 Phase 2A Proof-Of-Concept Study

Marketwired June 27, 2014

Revive Therapeutics Ltd. Submits Pre-IND Package to the US FDA for Its Gout Drug Candidate, REV-002

Marketwired June 5, 2014

Revive Therapeutics Ltd. Announces Results for the Three and Nine Months Ended March 31, 2014

Marketwired May 27, 2014

Revive Therapeutics Ltd. Provides Statement Regarding Trading Activity

Marketwired May 27, 2014

Revive Therapeutics Ltd. Announces Positive Pre-Clinical Results for Rett Syndrome, A Rare Disease

Marketwired May 14, 2014